Boston University Social Innovation on Drug Resistance Program
Advocate Member
Drug resistance is an inevitable biological process driven by evolution, but made worse by human behavior, threatening to usher in a post-antibiotic era. While the new products created from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator s (CARB-X) preclinical product development support are an important step in preventing that; an equally important challenge is to understand the impact of human behavior on the evolution of drug-resistant microbes. The tools for this effort will be interdisciplinary, rooted in the social sciences.
To advance these important goals, the Institute for Health System Innovation & Policy and CARB-X created the Social Innovation on Drug Resistance (SIDR) Program, an interdisciplinary postdoctoral fellowship program focused on the interaction of human behavior and drug-resistant infections.
European Investment Bank and BioVersys sign a financing agreement of up to €20 million to facilitate the development of new treatments against life-threatening resistant bacterial infections. The venture debt loan is financed under the Infectious Diseases Finance Facility set up as part.
Switzerland: BioVersys Receives €20 Million in EU Financing to Support Development of New Antibiotics b3cnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from b3cnewswire.com Daily Mail and Mail on Sunday newspapers.
Date Time
Ludwig Cancer Research scientists to present advances in immunotherapy, cancer metabolism
APRIL 10, 2021, NEW YORK – Ludwig Cancer Research released today the full scope of research to be presented by Ludwig-affiliated scientists at the April 9-14 American Association for Cancer Research (AACR) Annual Meeting, the first of two meetings which will be held online this year.
“The AACR Annual Meeting has long served as major opportunity for cancer researchers at all stages of their careers and from all over the world to meet, exchange ideas and forge collaborations to advance the study and treatment of cancer,” said Chi Van Dang, scientific director of the Ludwig Institute for Cancer Research and Editor-in-Chief of AACR’s Cancer Research journal. “The COVID-19 pandemic may have disrupted the physical gathering, but the intellectual exchange it enables will continue unimpeded. Ludwig and its scientists are excited about participating in that exchange.”
Zimbabwe scores gains in Tuberculosis (TB) treatment and control despite COVID-19 disruptions - Zimbabwe reliefweb.int - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reliefweb.int Daily Mail and Mail on Sunday newspapers.